Bang Heejin, Ahn Soomin, Ji Kim Eun, Kim Seung Tae, Park Ha Young, Lee Jeeyun, Kim Kyoung-Mee
Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea; Center of Companion Diagnostics, Samsung Medical Center, Seoul, Republic of Korea.
Center of Companion Diagnostics, Samsung Medical Center, Seoul, Republic of Korea; Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea.
Pathol Res Pract. 2020 Jan;216(1):152734. doi: 10.1016/j.prp.2019.152734. Epub 2019 Nov 11.
Rapamycin-insensitive companion of mTOR (RICTOR) is a key component of mammalian target of rapamycin (mTOR) complex 2 (mTORC2), and promotes cellular proliferation and survival through the activation of downstream AGC kinase family members. The amplification of RICTOR has been proposed as a therapeutically relevant genomic alteration. However, other than next-generation sequencing, precise diagnostic methods to detect RICTOR amplification in advanced solid cancers have not been fully explored. We performed immunohistochemistry (IHC) analysis on solid tumor tissues from 435 cancer patients. Overexpression of RICTOR was found in 213 cases (49.0 %: 1+, 29.4 %; 2+, 15.2 %; 3+, 4.4 %) consisting of 111 colorectal cancers, 42 gastric cancers, 16 renal cell carcinomas, 8 soft tissue sarcomas, 6 hepatocellular carcinomas, 6 cholangiocarcinomas, 4 lung cancers, and 37 other tumors. RICTOR overexpression was heterogeneous (stained < 50 % of the tumor volume) in 32.4 % (12/37) of IHC-positive cases. We performed fluorescence in situ hybridization (FISH) in 37 RICTOR-overexpressed IHC-positive cases (1+, 12; 2+, 11; 3+, 14) and 13 IHC-negative solid tumors. FISH enabled us to detect RICTOR amplification in 7/12 (58.3 %) IHC 1+, 10/11 (90.9 %) IHC 2+, and 11/14 (78.6 %) IHC 3+ cases. In total, there was amplification in 75.7 % (n = 28) of the RICTOR-overexpressed cases, according to FISH. There was RICTOR amplification in only 7.7 % of the RICTOR IHC-negative cases. RICTOR amplification was significantly more common in IHC-positive cases than in IHC-negative cases (p < 0.0001). The IHC results correlated well with those of FISH (r = 0.60). RICTOR overexpression is more common in solid tumors than previously reported in cases detected by next-generation sequencing. This discrepancy may be caused by intratumoral heterogeneity. In conclusion, heterogeneous RICTOR overexpression is common in solid tumors and RICTOR IHC can be used as a screening tool to detect RICTOR amplification.
雷帕霉素不敏感的mTOR伴侣蛋白(RICTOR)是雷帕霉素靶蛋白(mTOR)复合物2(mTORC2)的关键组成部分,通过激活下游AGC激酶家族成员促进细胞增殖和存活。RICTOR的扩增被认为是一种与治疗相关的基因组改变。然而,除了二代测序外,在晚期实体癌中检测RICTOR扩增的精确诊断方法尚未得到充分探索。我们对435例癌症患者的实体瘤组织进行了免疫组织化学(IHC)分析。在213例病例(49.0%:1+,29.4%;2+,15.2%;3+,4.4%)中发现RICTOR过表达,包括111例结直肠癌、42例胃癌、16例肾细胞癌、8例软组织肉瘤、6例肝细胞癌、6例胆管癌、4例肺癌和37例其他肿瘤。在32.4%(12/37)的IHC阳性病例中,RICTOR过表达呈异质性(染色肿瘤体积<50%)。我们对37例RICTOR过表达的IHC阳性病例(1+,12例;2+,11例;3+,14例)和13例IHC阴性实体瘤进行了荧光原位杂交(FISH)检测。FISH检测发现,在IHC 1+的病例中,7/12(58.3%)存在RICTOR扩增;在IHC 2+的病例中,10/11(90.9%)存在RICTOR扩增;在IHC 3+的病例中,11/14(78.6%)存在RICTOR扩增。根据FISH检测,在RICTOR过表达的病例中,共有75.7%(n = 28)存在扩增。在RICTOR IHC阴性病例中,只有7.7%存在RICTOR扩增。RICTOR扩增在IHC阳性病例中比在IHC阴性病例中更常见(p < 0.0001)。IHC结果与FISH结果相关性良好(r = 0.60)。RICTOR过表达在实体瘤中比二代测序检测的病例中更常见。这种差异可能是由肿瘤内异质性引起的。总之,异质性RICTOR过表达在实体瘤中很常见,RICTOR IHC可作为检测RICTOR扩增的筛查工具。